Late Tuesday, after a fifth buyout offer from Takeda, Shire said the Japanese drugmaker had finally landed on a proposal worth recommending to shareholders. It’s a cash-and-stock bid now worth $64 billion or so, about $4 billion more than its first offer.
Shire and Takeda come to terms with a $64B deal, the biggest pharma M&A in years
Leave a Comment